Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
The paradoxical coexistence of spontaneous tumor antigen-specific immune responses with progressive disease in cancer patients furthers the need to dissect the molecular pathways involved in tumor-induced T cell dysfunction. In patients with advanced melanoma, we have previously shown that the cancer-germline antigen NY-ESO-1 stimulates spontaneous NY-ESO-1-specific CD8(+) T cells that up-regulate PD-1 expression. We also observed that PD-1 regulates NY-ESO-1-specific CD8(+) T cell expansion upon chronic antigen stimulation. In the present study, we show that a fraction of PD-1(+) NY-ESO-1-specific CD8(+) T cells in patients with advanced melanoma up-regulates Tim-3 expression and that Tim-3(+)PD-1(+) NY-ESO-1-specific CD8(+) T cells are more dysfunctional than Tim-3(-)PD-1(+) and Tim-3(-)PD-1(-) NY-ESO-1-specific CD8(+) T cells, producing less IFN-γ, TNF, and IL-2. Tim-3-Tim-3L blockade enhanced cytokine production by NY-ESO-1-specific CD8(+) T cells upon short ex vivo stimulation with cognate peptide, thus enhancing their functional capacity. In addition, Tim-3-Tim-3L blockade enhanced cytokine production and proliferation of NY-ESO-1-specific CD8(+) T cells upon prolonged antigen stimulation and acted in synergy with PD-1-PD-L1 blockade. Collectively, our findings support the use of Tim-3-Tim-3L blockade together with PD-1-PD-L1 blockade to reverse tumor-induced T cell exhaustion/dysfunction in patients with advanced melanoma.
Fourcade
Julien
J
Department of Medicine and Division of Hematology/Oncology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA.
Sun
Zhaojun
Z
Benallaoua
Mourad
M
Guillaume
Philippe
P
Luescher
Immanuel F
IF
Sander
Cindy
C
Kirkwood
John M
JM
Kuchroo
Vijay
V
Zarour
Hassane M
HM
D015703:Antigens, CD / Q000096:biosynthesis / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology; D051017:Apoptosis Regulatory Proteins / Q000096:biosynthesis / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D000072597:Hepatitis A Virus Cellular Receptor 2; D006801:Humans; D007111:Immunity, Cellular; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D007376:Interleukin-2 / Q000096:biosynthesis / Q000276:immunology; D008545:Melanoma / Q000276:immunology* / Q000473:pathology; D008565:Membrane Proteins / Q000096:biosynthesis / Q000276:immunology*; D061026:Programmed Cell Death 1 Receptor; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000276:immunology; D015854:Up-Regulation
D015703:Antigens, CD; D000951:Antigens, Neoplasm; D051017:Apoptosis Regulatory Proteins; C104948:CTAG1B protein, human; D018984:Epitopes, T-Lymphocyte; C448908:HAVCR2 protein, human; D000072597:Hepatitis A Virus Cellular Receptor 2; D007376:Interleukin-2; D008565:Membrane Proteins; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma
J Immunol. 2009 May 1;182(9):5240-9
19380770
J Immunol. 2005 Feb 1;174(3):1751-9
15661941
J Virol. 2009 Sep;83(18):9122-30
19587053
J Exp Med. 2006 Oct 2;203(10):2281-92
16954372
Nat Med. 2006 Oct;12(10):1198-202
16917489
Blood. 2007 Aug 1;110(3):928-36
17440051
Am J Reprod Immunol Microbiol. 1988 Oct;18(2):47-51
2467568
Nature. 2002 Jan 31;415(6871):536-41
11823861
J Immunother. 2008 Oct;31(8):781-91
18779741
Nat Immunol. 2003 Nov;4(11):1093-101
14556005
J Exp Med. 2008 Nov 24;205(12):2763-79
19001139
Nature. 2006 Feb 9;439(7077):682-7
16382236
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4760-5
10781081
Nat Immunol. 2009 Jan;10(1):29-37
19043418
Nat Immunol. 2003 Nov;4(11):1102-10
14556006
J Exp Med. 2006 Jun 12;203(6):1413-8
16754722
J Exp Med. 1998 Apr 20;187(8):1349-54
9547346
Annu Rev Immunol. 2006;24:175-208
16551247
Nat Immunol. 2005 Dec;6(12):1245-52
16286920
Nature. 2006 Sep 21;443(7109):350-4
16921384